Astellas and Celgene-backed immuno-oncology therapy developer Oncorus has filed to raise up to $86.3m following more than $150m in funding.
US-based cancer immunotherapy developer Oncorus has filed for an $86.3m initial public offering that would allow pharmaceutical firms Astellas and Celgene to exit.
Oncorus is working on viral immunotherapies to treat cancer, and its lead product candidate, ONCR-177, utilises Herpes Simplex Virus (HSV) type 1 to stimulate the immune system to fight and destroy tumours.
The IPO proceeds will fund phase 1 clinical trials for ONCR-177 in types of cancer such as breast cancers and cutaneous tumours in addition…
